Prescription drug · NDA
Firdapse (Amifampridine phosphate) NDC 69616-211
Amifampridine phosphate 10 mg/1 · Tablet · Oral · Catalyst Pharmaceuticals, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 69616-211-03 | 69616021103 | 240 TABLET in 1 BOTTLE, PLASTIC (69616-211-03)Marketed from Jan 7, 2019 | |
| 69616-211-06 | 69616021106 | 12 BLISTER PACK in 1 CARTON (69616-211-06) / 10 TABLET in 1 BLISTER PACK (69616-211-04)Marketed from Jan 7, 2019 | |
| 69616-211-08 | 69616021108 | 60 TABLET in 1 BOTTLE, PLASTIC (69616-211-08)Marketed from Jan 7, 2019 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Firdapse
- Generic name (nonproprietary)
- amifampridine phosphate
- Active ingredients
- Amifampridine phosphate — 10 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Catalyst Pharmaceuticals, Inc.NDC labeler code 69616
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 208078
- Marketing start
- Listing expires
- Other FDA classes
- Potassium Channel Antagonists (Mechanism)
- Identifiers
- Product ID 69616-211_4f94edd2-b6a8-264d-e063-6294a90a89dfSPL ID 4f94edd2-b6a8-264d-e063-6294a90a89dfSPL set ID f015fe60-3128-4a43-8c31-19fc6b5def3fRxCUI 2106343, 2107518UNII 8HF8FIN815
- Pharmacologic class
- Potassium Channel Blocker
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N469616021103followed by a unit qualifier and the quantityPackage 69616-0211-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
FIRDAPSE ® is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older. FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 69616-211
- What is NDC 69616-211?
- 69616-211 is the product NDC for Firdapse (amifampridine phosphate), Amifampridine phosphate 10 mg/1 tablet, listed with the FDA by Catalyst Pharmaceuticals, Inc.. It has 3 package NDCs, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Firdapse (Amifampridine phosphate).
- What is the active ingredient?
- Amifampridine phosphate.
- Who is the labeler?
- Catalyst Pharmaceuticals, Inc., NDC labeler code 69616. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Firdapse?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.